Baricitinib is the first once-daily oral selective JAK1 (Janus kinase) and JAK2 inhibitor for the treatment of moderate to severe active rheumatoid arthritis.
Baricitinib is a Janus kinase inhibitor, which functions by inhibiting the activity of selective JAK1 and JAK2 enzymes, interfering with the JAK-STAT signalling pathway.
Barcitinib is Off-white to white powder and slightly soluble in water.
CAS NO.: 1187594-09-7
Notice: If the compound involved in patent protection, do not use for commercial purposes, and only for the purpose of analysis and research experiments. If it’s sold to countries which constitute patent infringement, All the risks corresponding are unrelated to our company.